Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients: Significance and therapeutic implications  by Pol, Stanislas et al.
Kidney International, Vol. 44 (1993), pp. 1097—1100
Hepatitis C virus RNA in anti-HCV positive hemodialyzed
patients: Significance and therapeutic implications
STANISLAS POL, RAFFAELLA ROMEO, BRIGITTE ZINs, Flt&NçoIsE DRIss, BERNARD LEBKIRI,
F1t'NcoIsE CARNOT, PIERRE BERTHELOT, and CHRISTIAN BRECHOT
Unite d'Hepatologie, Banque dii sang and Laboratoire d'Anatomo-Pathologie, Hôpital Laënnec, Service d'Hémodialyse de l'Hôpital Necker,
de Ia Clinique de l'Alma and dii Parc, Monceau; Laboratoire Hybridotest, Institut Pasteur; INSERM U-99 and U-370, Paris, France
Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients:
Significance and therapeutic implications. About 25% of French hemo-
dialysis patients have antibodies against the hepatitis C virus (HCV),
which may reflect either past or active HCV infection. It is important to
evaluate the significance of these antibodies, as most hemodialysis
patients are candidates for kidney transplantation and have normal
transaminase activities despite biopsy-proven chronic hepatitis. We
prospectively assayed HCV viremia with the nested polymerase chain
reaction in 61 patients on maintenance hemodialysis who had anti-HCV
antibodies detectable in second generation tests (ELISA2 or RIBA2).
HCV RNA was repeatedly detected in the serum of 52(85.2%) patients.
Liver biopsy, which was performed in 17 cases, revealed chronic
hepatitis in 16 cases (including 2 of cirrhosis) and steatosis in one.
Hypertransaminasemia was observed in only 3 1.3% and 30.8% of
patients with chronic hepatitis and HCV viremia, respectively. Anti-
HCV antibodies are frequently associated with HCV viremia, resulting
usually in chronic hepatitis, although hypertransaminasemia is uncom-
mon. HCV viremia reflects both post-transfusional and community-
acquired HCV infection. These findings suggest a need for liver biopsy
and antiviral treatment before kidney transplantation. The isolation of
anti-HCV positive subjects in the dialysis setting should be evaluated to
reduce patient-to-patient transmission of HCV.
Hemodialyzed patients and kidney transplant recipients are
often multiply transfused and are thus frequently infected by
hepatotropic viruses, mainly hepatitis B virus (HBV) and
hepatitis C virus (HCV) [1—4]. HCV is a single-stranded RNA
virus which is a major cause of post-transfusional and sporadic
"non-A,non-B" hepatitis. A high prevalence of anti-HCV an-
tibodies has been reported in hemodialysis patients in various
geographic areas (5 to 85% worldwide, 25% in France) [5]
relative to blood donors (around 0.7%) [6]. This high frequency
of HCV infection is related to the number of blood transfusions
and the duration of dialysis [7, 8].
The significance of anti-HCV antibodies is not clear; they
may reflect either past, resolved infection or active infection
with viral replication. There are few data on HCV viremia in
hemodialysis patients. Two recent studies reported a high
frequency of HCV viremia in hemodialysis patients [9] as well
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as kidney transplant recipients [10], but there was no informa-
tion about liver histology. The significance of anti-HCV anti-
bodies is important for several reasons: (1) some hemodialysis
patients are candidates for kidney transplantation, which is
usually associated with a worsening of liver lesions [111; (2) at
least 50% of these patients may have normal serum transami-
nase activity despite biopsy-proven chronic hepatitis [12]; (3)
viremic patients could be the source of nosocomial transmission
of HCV in hemodialysis units; (4) a-interferon treatment may
be of value before kidney transplantation.
The aim of this prospective study was to evaluate the
significance of anti-HCV antibodies in hemodialysis patients.
Methods
Inclusion criteria were chronic dialysis and the presence of
anti-HCV antibodies.
Patients
In May 1992, we conducted a prospective study of 61
anti-HCV positive patients who were undergoing dialysis in
three separate centers. There were 31 men and 30 women, with
a mean age of 56 years. The mean dialysis period was 9 6
years, and all but six patients who had never been given blood
products had received more than 5 units of blood.
Methods
Serological assays. HBsAg, antiHBs and antiHBc antibodies
were detected using an enzyme-linked-immunosorbent assay
(Institut Pasteur, Paris, France), according to the manufactur-
er's instructions.
Serum antibodies to HCV were detected with the second-
generation HCV enzyme-linked immunosorbent assay
(ELISA2) or recombinant immunoblot assay (RIBA2) from
Ortho Diagnostic, according to the manufacturer's instructions.
These assays detect antibodies directed against five recombi-
nant HCV antigens: 5-1-1 polypeptide, produced in E. coli
clones of HCV as a fusion protein with human superoxide
dismutase (SOD); the SOD fusion protein C-lOO-3 produced by
selected yeast clones; SOD protein itself, which is used as a
control; and C-33-C and C-22-3, which are respectively non-
structural and structural proteins.
HCV RNA detection by means of the polymerase chain
reaction. HCV RNA purification. RNA was extracted from 150
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.d of serum, reverse transcribed into cDNA and amplified by
PCR as previously described [13, 14]. Briefly, the serum was
diluted to a final volume of 800 d in 0.05 M Tris-HCI (pH 7.5),
0.01 M EDTA, 0.1 M NaCl and 0.5% sodium dodecyl sulphate,
digested with 500 g/ml proteinase K, extracted with phenoll
chloroform, and precipitated with ethanol.
Preparation and amp1flcation of HCV cDNA. To improve
the accuracy of the nested PCR assay, HCV cDNA was
amplified using a modified nested PCR method [13] and primers
located in the 5' non-coding region [15]. Amplified products
were stained with ethidium bromide and hybridized with a
radiolabeled oligonucleotide probe within the amplified se-
quence. Drastic contamination-control measures were applied,
including physical separation of the laboratories involved in the
pre- and post-PCR steps, and inclusion of negative controls
throughout (lysis buffer and normal serum). The results were
only taken into account when all these controls were negative.
Each sample was tested in at least two different runs. In
addition, the results were recently validated by the screening of
positive and negative reference samples from an international
panel (a gift of Dr. I. Reesink, blood bank, Amsterdam).
Primers. Outer primers were antisense (SRi) 5'-TGCACG-
GTCTACGAGACCTC-3', corresponding to position (—)21
(—)20 of the prototype HCV cDNA nucleotide sequence, and
(SF1) 5'-GCCATGGGGTTAGTATGAGT-3', corresponding to
position (—)259/(—)240. Inner primers were antisense (SR2)
5'-GGGCACTCGCAAGCACCCTAT-3' (position (—)251(—)45)
and (SF2) 5'-GTGCAGCCTCCAGGACCCCC-3', correspond-
ing to position (—)235/(—)217. The probe was 5'-ACACCG-
GAATTGCCAGGACGACCGGGTCCTflCTTG-3' (position
(—)1761(—)138).
Serum transaminases activities. Serum aspartate aminotrans-
ferase and alanine aminotransferase activities were measured in
every case by using the serum from the same blood sample as
that used for the serological assays. Enzyme activities were
assayed using a fast centrifugal analyzer (Cobas Bio Roche).
Hypertransaminasemia was arbitrarily defined as a value over
1.5-fold the upper limit of normal.
Histopathological analysis
Liver biopsy samples were embedded in paraffin. Sections
were stained with hematoxylin and eosin and Pens stain.
Chronic liver disease was classified as chronic hepatitis or
cirrhosis according to criteria which have been recently empha-
sized [16]. Indeed, chronic persistent hepatitis and chronic
active hepatitis are not distinct diseases, and one could change
to the other.
Results
All the 61 anti-HCV-positive HBs antigen-negative patients
had anti-HCV antibodies detectable in the second-generation
serological assays, and HCV viremia was repeatedly detected
in the serum of 52 (85.2%) patients (Table 1, Fig. 1).
A liver biopsy was performed in 17 patients who were
candidates for kidney replacement. Chronic hepatitis was diag-
nosed in 16 cases (cirrhosis in two), and steatosis in one patient.
Only five of the 16 patients (31.3%) with biopsy-proven chronic
hepatitis had increased transaminase activities.
Fourteen of the 15 patients who had HCV viremia had
chronic liver disease, including one patient with active cirrhosis
Table 1. Results of HCV RNA detection in the 61 anti-HCV-positive
hemodialyzed patients, according to the results of transaminases
activities and liver biopsy
HCV RNA
positivity
N(%)
HCV RNA
negativity
N(%)
Overall population 52 (85.2) 9 (14.8)
Hypertransaminasemia 16 (30.8) 2 (22.2)
Patients who underwent 15 (88.2) 2 (11.8)
liver biopsy
Biopsy-proven chronic l4 (93.3) 2 (100)
hepatitis
a including 2 with cirrhosis
and one with cirrhosis but no histological features of active
disease (Table 1). Hypertransaminasemia was observed in four
of these 15 viremic patients (26.7%). Two patients without
detectable HCV viremia who underwent liver biopsy also had
chronic active hepatitis; one of these two patients with chronic
hepatitis and no detectable HCV viremia had increased
transaminase activities.
In the 52 PCRHCV-positive subjects, hypertransaminasemia
was present in only 16 (30.8%), while of the 9 PCR-HCV-
negative patients only one (11.1%) had hypertransaminasemia.
Six patients had never received blood transfusions; they all
had HCV viremia and two (33.3%) had hypertransaminasemia.
Forty-six of the 54 patients (85.2%) who had received blood
transfusion had HCV viremia, and 11(20.0%) had hypertran-
saminasemia.
Finally, abdominal ultrasonography was normal in all but the
two patients with cirrhosis who had signs of liver dysmorphy
and portal hypertension.
Discussion
Our results show a high frequency of HCV RNA in the serum
of French anti-HC V-positive patients on hemodialysis, indicat-
ing the existence of on-going viral replication, as recently
described in the Far East [9]. In addition, HCV viremia usually
results in chronic active hepatitis in hemodialyzed patients,
thus evidencing the need of therapeutic antiviral trials.
This high frequency of HCV viremia (85.2%) in hemodialysis
patients who were not selected on the basis of liver function
tests suggests that the procedure is associated with an increased
risk of progression to chronic infection. Indeed, in the general
population, around 50% of HCV infection results in chronic
hepatitis [17]. An increased risk of chronic HCV infection in
hemodialyzed patients, as in the case of HBV infection, may
reflect an immunologic deficit related either to uremia or to
hemodialysis [181.
It is noteworthy that hypertransaminasemia was observed in
only 31% of the patients who had HCV viremia and in less than
30% of those who had biopsy-proven chronic hepatitis. It
should be noted that this does not preclude previous intermit-
tent increase of transaminase activities in some of our patients.
These results are similar to those reported recently in symptom-
free blood donors with serum anti-HCV antibodies [19]. Sixteen
of 23 such patients had histological evidence of chronic hepa-
titis. All 16 patients had HCV viremia, including nine with
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Fig. 1. Detection of HCV-RNA in hemodialyzed patients by po/ymerase chain reaction. A. Ethidium bromide staining. B. Autoradiography after
32p hybridization. Abbreviations are: H20, polymerase chain reaction with mix alone; MW, molecular weight marker. Lanes 1, 3, 4, 5, 6 and 7
correspond to positive serum samples for HCV viremia; Lane 2 corresponds to a negative serum for HCV viremia.
normal alanine aminotransferase values, whereas seven HCV-
RNA negative patients had a normal liver histology. These
results in the overall population as well as in hemodialyzed
patients show that serum HCV viremia is a sensitive and
specific marker of liver disease in anti-HCV-positive subjects,
whatever the transaminase values.
A characteristic course of chronic hepatitis in hemodialyzed
patients has been reported, with no marked increase in serum
transaminases, mild liver-cell necrosis and inflammatory infil-
tration [12]. Nevertheless, this course, although remarkably
asymptomatic, may lead to a progressive aggravation of histo-
logical lesions and cirrhosis may ensue, as was the case in two
of our patients. The risk of worsening of the histological index
in hemodialyzed subjects raises the difficult problem of liver
biopsy. We consider that all anti-HCV-positive hemodialysis
patients who are candidates for kidney transplantation should
undergo liver biopsy (transcutaneous or transvenous route, or
"plugged" biopsy). Indeed, laboratory tests are of little value
for determining whether chronic liver disease is present and
chronic hepatitis is usually associated with an histological
worsening of the liver disease in kidney transplantation, what-
ever the HBsAg status [11]. Also, alpha-interferon therapy
might probably increase the risk of acute vascular rejection in
kidney recipients [20]. Thus, an antiviral treatment should
probably be given while these patients are waiting for a matched
allograft.
HCV may not be the only virus implicated in chronic active
hepatitis of HBs antigen-negative anti-HCV-positive hemodia-
lyzed patients. Biopsy-proven chronic hepatitis was indeed
observed in two anti-HCV-positive patients who had no evi-
dence of HCV viremia and who were protected against HBV
and had no detectable HBV DNA in their serum. This suggests
either HCV viremia fluctuated or that a non-A,non-B,non-C
virus is responsible for the chronic hepatitis.
Anti-HCV antibodies (and thus HCV viremia) usually corre-
lated with the duration of the dialysis period and the number of
blood transfusions [7, 8], which suggests two routes of HCV
transmission: community-acquired and post-transfusional in-
fection. The increasing use of recombinant erythropoietin and
the better efficiency of blood donor screening has probably
resulted in a dramatic decrease in post-transfusional HCV
hepatitis in these patients [21]. By contrast, the risk of nosoco-
mial or "community-acquired" HCV transmission persists.
This possibility is suggested by: (1) the six anti-HCV-positive
subjects from the present study who had never received blood
transfusions yet had HCV viremia; (2) outbreaks of non-
A,non-B hepatitis previously observed in the dialysis setting,
and unrelated to blood transfusions [22]. This hypothesis will
now require further evidence such as tests for the detection of
HCV on the dialysis machines (water filters, ultrafiltrates, etc.).
As with HBV, contamination of environmental surfaces
(swabs, clamps, gloves) and the use of the same dialysis shift
could be important risk factors. For these reasons, it should be
interesting to evaluate the efficacy of the segregation of anti-
HCV-positive patients and the complete sterilization of the
dialysis machines in limiting patient-to-patient transmission.
In conclusion, anti-HCV antibodies are generally associated
with HCV viremia in hemodialysis patients and reflect post-
transfusional as well as community-acquired HCV infection.
Although hypertransaminasemia is infrequent, HCV viremia
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usually results in a chronic hepatitis. These findings call for a
systematic sterilization of the dialysis machines, a segregation
of anti-HCV-positive patients in the dialysis setting, together
with a liver biopsy and antiviral treatment before kidney
transplantation.
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